Unpacking the Surge in Viking Therapeutics Stock Today

This afternoon we watched Viking Therapeutics rise 6.0% to a price of $53.8 per share. The Mid-Cap Pharmaceutical company is now trading -52.54% below its average target price of $113.36. Analysts have set target prices ranging from $90.0 to $138.0 per share for Viking Therapeutics, and have given the stock an average rating of buy.

Viking Therapeutics has an elevated short interest of 15.5%. The stock's short ratio, or the number of days needed for all shorts to cover their positions, is 3.63. Only 6.0% of the company's shares are owned by insiders, indicating that management does not have a deep alignment of interest with its shareholders. 75.2% of Viking Therapeutics shares are held by institutional investors, which indicates a high level of confidence in the stock.

Institutions Invested in Viking Therapeutics

Date Reported Holder Percentage Shares Value
2024-03-31 FMR, LLC 15% 16,347,292 $879,484,297
2024-03-31 Blackrock Inc. 8% 8,274,174 $445,150,554
2024-03-31 Vanguard Group Inc 7% 7,785,724 $418,871,945
2024-03-31 Avoro Capital Advisors LLC 3% 3,590,000 $193,141,997
2024-03-31 State Street Corporation 3% 3,326,567 $178,969,302
2024-03-31 Geode Capital Management, LLC 2% 2,326,779 $125,180,708
2024-03-31 Alliancebernstein L.P. 1% 1,560,878 $83,975,235
2024-03-31 Pictet Asset Management Holding SA 1% 1,378,036 $74,138,335
2024-03-31 Viking Global Investors, L.P. 1% 1,094,940 $58,907,771
2024-03-31 Voya Investment Management LLC 1% 1,068,597 $57,490,517

For these reasons, we consider that the Viking Therapeutics is the subject of mixed market sentiment.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.